The Central Drugs Standard Control Organization (CDSCO) panel has requested further study on the safety and effectiveness of using tenecteplase at a dosage of 0.25 mg/kg for treating acute ischemic stroke. This request was made to the pharmaceutical company Boehringer Ingelheim. The study will focus on evaluating the potential risks and benefits of this treatment option. The CDSCO panel’s decision emphasizes the importance of thorough research to ensure the safety and efficacy of medical interventions. This news underscores the ongoing efforts to improve the treatment options available for patients with acute ischemic stroke.
Source link
CDSCO Panel Tells Boehringer Ingelheim
